What's the Maximum Metformin Dose Per Day?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The maximum FDA-approved adult metformin immediate-release (IR) dose is 2,550 mg/day, divided into 2 to 3 doses with meals.
• The maximum extended-release (ER) dose is 2,000 mg/day, taken once daily with the evening meal.
• Pediatric (10 to 16 years) maximum is 2,000 mg/day.
• Doses above 2,000 mg/day rarely produce additional A1C reduction. Most clinical benefit is captured between 1,500 and 2,000 mg/day.
• Metformin should be reduced or stopped if eGFR falls below 45 mL/min/1.73 m² (American Diabetes Association, Standards of Care 2024).

Direct answer (40-60 words, snippet-optimized)

The maximum FDA-approved metformin dose is 2,550 mg per day for immediate-release tablets, divided across 2 to 3 doses with meals, and 2,000 mg per day for extended-release. In children 10 to 16, the maximum is 2,000 mg/day. Doses above 2,000 mg rarely improve glycemic control further but do increase GI side effects.

Table of contents

1. The 30-second answer
2. The maximum dose for immediate-release vs extended-release
3. Why 2,550 mg is the IR ceiling and 2,000 mg is the ER ceiling
4. The dose-response curve flattens above 2,000 mg
5. Titration schedule from start to maximum
6. Pediatric maximum dose
7. When to reduce or stop metformin (kidney function)
8. Side effects at maximum dose
9. Maximum dose with other diabetes medications
10. Lactic acidosis risk
11. FAQ
12. Sources
13. Footer disclaimers

The maximum dose for immediate-release vs extended-release

Metformin comes in two main formulations, and they have different maximum daily doses.

Immediate-release (IR) metformin is the original formulation, available in 500 mg, 850 mg, and 1,000 mg tablets. The maximum FDA-approved adult dose is 2,550 mg/day, typically given as either:

• 850 mg three times daily with meals (2,550 mg total), or
• 1,000 mg twice daily plus 500 mg once daily (2,500 mg total)

In practice, most patients on maximum-dose IR take 1,000 mg twice daily, which is 2,000 mg total. The 2,550 mg ceiling is rarely reached because the marginal A1C benefit above 2,000 mg is small and GI side effects climb steadily.

Extended-release (ER) metformin is a once-daily formulation available in 500 mg, 750 mg, and 1,000 mg tablets. The maximum FDA-approved adult dose is 2,000 mg/day, taken with the evening meal. The ER formulation can't be titrated above 2,000 mg without GI tolerability issues, partly because the slower absorption profile concentrates the dose in the gut over a longer window.

A patient on maximum-dose ER who wants to push higher can switch to IR and titrate to 2,550 mg, but most clinicians don't do this since the additional A1C reduction is minimal.

Why 2,550 mg is the IR ceiling and 2,000 mg is the ER ceiling

The maximum doses come from clinical trial data and FDA labeling decisions made when the drugs were approved.

For IR metformin, the original 1995 U.S. approval cited dose-finding studies showing that 2,550 mg/day produced the largest A1C reduction in monotherapy trials, with a clear plateau above that. Higher doses were tested but rejected because they didn't improve outcomes and increased GI symptoms substantially.

For ER metformin, the maximum is 2,000 mg/day because the formulation's pharmacokinetic profile changes at higher tablet loads. Each ER tablet is engineered to release metformin slowly over 8 to 12 hours. Stacking 2,000 mg of ER releases metformin over 16 hours; pushing to 2,500 mg or 3,000 mg would extend the release window into territory where GI tolerability degrades and the slow-release advantage disappears.

The FDA labels for both formulations also restrict dose increases to no more than 500 mg per week, since rapid escalation is one of the main causes of GI dropout.

The dose-response curve flattens above 2,000 mg

A consistent finding across metformin trials is that A1C reduction is roughly proportional to dose up to about 1,500 to 2,000 mg/day, then flattens.

DeFronzo et al. (NEJM 1995) tested doses from 500 mg/day to 2,500 mg/day in type 2 diabetes patients. A1C reductions were:

The jump from 2,000 to 2,500 mg added only 0.2% A1C reduction. The jump from 1,000 to 2,000 mg added 0.8%. The dose-response curve flattens hard above 2,000 mg.

This is why most clinicians treat 2,000 mg/day (1,000 mg twice daily IR or 2,000 mg once daily ER) as the practical ceiling. Pushing higher rarely improves glycemic control enough to justify the extra GI side effects.

For weight loss specifically, the dose-response data is even less clear. Most metformin weight-loss effect (modest, around 2 to 3 kg over 6 to 12 months in non-diabetic patients) appears to be captured at 1,500 mg/day with no clear additional benefit at higher doses.

Titration schedule from start to maximum

Metformin is titrated up gradually to reduce GI side effects. The FDA-approved schedule for IR metformin is:

For ER metformin:

The label allows weekly increases of 500 mg, but in practice many clinicians titrate slower (every 2 weeks) for patients with significant GI symptoms. Patients who titrate too quickly often quit the medication because of nausea, diarrhea, or abdominal cramping that resolves with slower escalation.

For more on starting medications, see our getting started guide.

Pediatric maximum dose

Metformin is FDA-approved for type 2 diabetes in children 10 years and older. The pediatric maximum dose is 2,000 mg/day for both IR and ER formulations, divided into 2 doses for IR or once daily for ER.

The lower pediatric ceiling reflects two considerations. First, pediatric trial data didn't establish meaningful additional benefit above 2,000 mg/day. Second, body weight in adolescents starting metformin tends to be lower than in adults, so the milligram-per-kilogram exposure at 2,000 mg/day is comparable to or higher than an adult on 2,550 mg/day.

Children under 10 don't have FDA approval for metformin, though it's sometimes used off-label in younger pediatric patients with severe insulin resistance under endocrinology supervision.

When to reduce or stop metformin (kidney function)

Metformin is renally cleared, so kidney function dictates the maximum safe dose. The 2016 FDA labeling update set kidney-function-based dosing guidance:

The American Diabetes Association's Standards of Care 2024 echoes this: metformin should generally be discontinued when eGFR falls below 30 mL/min/1.73 m². The risk in advanced kidney disease is metformin accumulation, which raises lactic acidosis risk.

For patients on maximum dose with declining renal function (common with aging), the typical sequence is: full dose at eGFR ≥60, dose reduction at eGFR 30 to 44, and discontinuation below eGFR 30. Renal function should be checked annually in stable patients and more often in patients with comorbidities affecting kidney function.

Side effects at maximum dose

GI side effects are the dominant issue at maximum-dose metformin. In the DeFronzo trials, side effect rates by dose were approximately:

• Diarrhea: 25% at 2,000 mg/day, 30% at 2,500 mg/day, vs 12% at 500 mg/day
• Nausea: 12% at 2,000 mg/day, 15% at 2,500 mg/day, vs 7% at 500 mg/day
• Abdominal pain: 10% at 2,000 mg/day, 12% at 2,500 mg/day
• Metallic taste: 5 to 10% across doses
• Vitamin B12 deficiency (long-term, especially with maximum doses for >5 years): about 6 to 9% of patients

The B12 deficiency issue is one reason most clinicians recommend annual B12 testing for patients on maximum-dose metformin long-term. Symptoms (peripheral neuropathy, cognitive changes, anemia) can be subtle and overlap with diabetes itself.

GI side effects often improve when patients switch from IR to ER at the same daily dose. The slower-release formulation is gentler on the gut.

For more on metformin and weight, see our low dose metformin guide.

Maximum dose with other diabetes medications

Metformin at maximum dose is frequently combined with other diabetes drugs, especially when monotherapy doesn't achieve A1C goal. Common combinations and any dose interaction notes:

Combination therapy generally allows lower doses of each individual drug while achieving similar A1C reduction, which is why metformin maximum dose is more often pushed in monotherapy than in combination regimens.

Lactic acidosis risk

Lactic acidosis is metformin's most serious adverse effect, but it's rare. Estimated incidence is 3 to 10 cases per 100,000 patient-years (Salpeter et al., Cochrane Database 2010), and most cases occur in patients with significant kidney impairment, sepsis, severe heart failure, or alcohol intoxication.

The maximum-dose group is not at substantially higher risk than the typical-dose group, as long as kidney function is normal. Risk factors for lactic acidosis include:

• eGFR <30 mL/min/1.73 m²
• Dehydration (severe diarrhea, vomiting, or use of contrast dye for imaging)
• Acute heart failure or hypoxia
• Acute alcohol intoxication
• Recent surgery with prolonged fasting

The FDA's 2016 metformin label update softened earlier warnings about contrast dye, since most contrast-induced kidney injury is transient. Current guidance is to hold metformin only if eGFR is below 60 and contrast is needed, or if other contrast-related risk factors are present.

If a patient on maximum-dose metformin develops new symptoms of lactic acidosis (hyperventilation, severe muscle pain, lethargy, abdominal pain), the medication should be stopped and the patient evaluated emergently. Lab confirmation is via arterial blood gas and lactate level.

FAQ

What's the maximum metformin dose per day?

For adults: 2,550 mg/day for immediate-release tablets (typically 850 mg three times daily) or 2,000 mg/day for extended-release tablets (once daily with dinner). For children 10 to 16: 2,000 mg/day for both formulations.

Why is the ER maximum lower than the IR maximum?

The extended-release formulation is engineered for slow absorption over 8 to 12 hours per tablet. Higher daily doses extend the release window past the point where GI tolerability and absorption efficiency hold up. ER above 2,000 mg/day produces no measurable benefit and more side effects.

Can I take 3,000 mg of metformin per day?

No. The FDA maximum is 2,550 mg/day for IR. Doses above this don't produce meaningful additional A1C reduction and significantly increase GI side effects. Some endocrinologists rarely push to 3,000 mg in select cases, but this is off-label and uncommon.

Is 2,000 mg of metformin a high dose?

It's the practical maximum dose for most patients. About 60 to 70% of patients on metformin in the U.S. take 2,000 mg/day or less. Pushing higher (to 2,550 mg) is uncommon and usually reserved for patients close to A1C goal who want to avoid adding a second drug.

How much A1C reduction at 2,000 mg vs 2,550 mg?

Roughly 1.8% A1C reduction at 2,000 mg vs 2.0% at 2,500 mg in DeFronzo et al. The 0.2% additional reduction at the highest dose is statistically real but clinically marginal.

Should I split my maximum dose into 2 or 3 doses?

For IR metformin at 2,000 mg/day, two doses (1,000 mg twice daily) is most common. At 2,550 mg/day, three doses (850 mg three times daily) reduces GI side effects compared to fewer larger doses. ER metformin is once daily regardless of total dose.

Can I take maximum-dose metformin if I have kidney disease?

It depends on eGFR. At eGFR ≥60, full dose is fine. At eGFR 45 to 59, the dose may stay the same with closer monitoring. At eGFR 30 to 44, the maximum is reduced to about 1,000 mg/day. Below eGFR 30, metformin should be stopped.

Does maximum-dose metformin help with weight loss?

Modestly. Most weight-loss effect of metformin (typically 2 to 3 kg over 6 to 12 months in non-diabetic patients) is captured at 1,500 mg/day. Pushing to 2,000 or 2,550 mg adds little additional weight loss and more side effects.

How long should I stay at the maximum dose?

Indefinitely, in most cases. Metformin's benefits depend on continued use. Patients who stop usually see A1C and weight rebound. Long-term safety data extends to 20+ years for many patients, with the main concern being B12 deficiency, which can be monitored and corrected.

What if I can't tolerate maximum-dose metformin?

Most patients tolerate 1,500 to 2,000 mg/day if they titrate gradually. If GI side effects don't resolve, switching from IR to ER often helps. If maximum-dose IR or ER is intolerable, settling at the highest tolerated dose (often 1,500 mg) is a reasonable strategy.

Can I take metformin with GLP-1 medications?

Yes. The combination is common and effective. Both work through different mechanisms (metformin reduces hepatic glucose output and improves insulin sensitivity; GLP-1s slow gastric emptying and stimulate insulin release). GI side effects can overlap, so titration of either drug should be slow.

What's the difference between the 850 mg and 1,000 mg IR tablets?

Functionally none, beyond making three-times-daily dosing math cleaner. 850 mg three times daily equals 2,550 mg (the maximum). 1,000 mg twice daily equals 2,000 mg. Some pharmacies stock both; most patients use 1,000 mg.

Related guides

• Metformin Maximum Dose Per Day: FDA Limits, Split Dosing Math, and When Higher Isn't Better
• What Is the Maximum Safe Dose of Metformin Per Day?
• How Much Metformin Can You Take in a Day: Maximum Doses, Timing, and the Safety Ceiling Explained
• Metformin Maximum Dosage Per Day: FDA Limits, Extended-Release Differences, and When Higher Isn't Better
• Maximum Dosage of Metformin Per Day: FDA Limits, Extended-Release vs. Immediate-Release, and When Higher Doses Backfire
• What Is the Maximum Dose of Metformin? FDA Limits, Safety Thresholds, and When Higher Isn't Better
• Tool: dosage calculator

Sources

1. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352:854-865.
3. Salpeter SR, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;CD002967.
4. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
5. U.S. Food and Drug Administration. Glucophage (metformin hydrochloride) prescribing information.
6. U.S. Food and Drug Administration. Glucophage XR (metformin extended-release) prescribing information.
7. Inzucchi SE, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668-2675.
8. Aroda VR, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754-1761.
9. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications. Lancet Diabetes Endocrinol. 2015;3:866-875.
10. Garber AJ, et al. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
11. Lipska KJ, et al. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-1437.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage and Glucophage XR are registered trademarks of Bristol-Myers Squibb. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.